首页> 外文会议>Annual meeting exposition of the Controlled Release Society >In Vitro Characterization of Concentration Enhancing Polymer Solid Dispersions Containing Itraconazole Produced by KinetiSol(R) Dispersing
【24h】

In Vitro Characterization of Concentration Enhancing Polymer Solid Dispersions Containing Itraconazole Produced by KinetiSol(R) Dispersing

机译:浓度的体外表征增强聚合物固体分散体,含有KINETISOL(R)分散产生的伊唑康唑

获取原文

摘要

Solid dispersions of itraconazole (ITZ) and various grades (LF, MF, HF) of the concentration enhancing polymer hypromellose acetate succinate (HPMCAS) were prepared by KinetiSol(R) Dispersing, a novel high energy solvent free manufacturing process for the production of solid dispersions, and characterized for solid state properties and in vitro dissolution performance. Inprocess results showed that the KinetiSol(R) Dispersing process was a rapid method for producing amorphous solid dispersions, with all batches demonstrating potencies between 95.0% to 105.0% of target and no significant degradation observed. All batches were also shown to be amorphous and in vitro dissolution testing showed that HPMCAS-LF provided the greatest degree and extent of supersaturation in neutral media, indicating that this composition could provide enhanced oral bioavailability of ITZ.
机译:通过KINETISOL分散制备浓度增强聚合物Hypromellose乙酸琥珀酸纤维素(HPMCAs)的伊唑酮(ITZ)和各种等级(LF,MF,HF)的固体分散体,这是一种用于生产固体的新型高能溶剂无溶剂制造方法分散体,其特征在于固态性质和体外溶出性能。矿产结果表明,运动醇(R)分散过程是生产无定形固体分散体的快速方法,所有批差论均为靶标的效率均为靶标含率,并且没有观察到显着的降解效率。观察到的疗效均有95.0%至105.0%。所有批次也被证明是无定形的,并且体外溶解试验显示HPMCA-LF在中性介质中提供的最大程度和程度的过饱和度,表明该组合物可以提供ITZ的增强的口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号